Intelligent Delivery Systems, Inc.
Intelligent Delivery Systems’ (“IDS”) mission is to provide an integrated and holistic approach to diagnosing and treating arterial disease. In support of this mission, IDS has developed a suite of “smart”, electrical conductance-enabled therapeutic devices (i.e., guidewires, catheters, balloons) for coronary and peripheral intervention that enables real-time, quantitative assessment of vessel lumen structure and function. The first device being commercialized within this suite of electrical conductance-enabled products is a .035” combination therapy-delivering (“workhorse”) and vessel sizing guidewire (the “35 Wire”) for use in the diagnosis and treatment of peripheral artery disease (PAD). The 35 Wire provides rail delivery for compatible interventional devices in addition to highly accurate cross-sectional area (CSA) and diameter measurements, without subjective interpretation or user variability, significant user training or negative impact on clinical workflow. We believe the 35 Wire will help address the void of strong point-of-care, diagnostic tools designed specifically for use in the peripheral vasculature and will materially improve work flow efficiency (including, importantly, reduce radiation exposure time to physician and patient), total cost of care, and patient outcome for peripheral intervention cases. Development activities are also currently underway for a 3-in-1 workhorse, sizing and pressure wire as well as a .014” coronary wire.
GRest is developing a “Best of Both Worlds” laparoscopic reversible gastric restrictive (“RGR”) device that is expected to provide the substantial, sustainable weight loss of invasive bariatric surgery (e.g., vertical sleeve gastrectomy), with the reversibility and anatomy preservation of implantable, adjustable gastric bands. The RGR design is currently being finalized for use in human clinical trials and an initial clinical/regulatory plan has been developed.
Retroperfusion, Inc. is developing minimally invasive, circulatory support catheters for patients with ischemic heart disease and critical limb ischemia (CLI) for both acute and chronic applications. The same platform technology can be used as a minimally-invasive, circulatory support catheter for acute and chronic ischemic heart disease patients and critical limb ischemia. It can also act as a shorter term, bridge therapy for acute patients requiring high-risk left main coronary artery intervention or presenting with cardiogenic shock or ST-elevated myocardial infarction as well as to minimize reperfusion injury through use of hypothermia during retroperfusion.
Pericardial Access, Inc.
PAC is developing a minimally-invasive platform technology for passage through the heart wall for delivery of various therapies and diagnostic tools in the pericardial space. PAC’s proprietary catheter system provides stable site selection and improved control for therapy via trans-atrial approach (from right atrium into the pericardial space). Once access has been attained, the PAC catheter can be used to deliver various diagnostic and therapeutic tools through the right atrial wall and into the area of interest.
GI Bionics LLC
The mission of GI Bionics is to develop innovative medical device technology for diagnosis of gastrointestinal diseases, in particular related to colonic and anorectal function. The primary product being developed is named Fecobionics. It is a wireless device that can measure the important physiological and biomechanical parameters such as the expulsion pressures and velocity during defecation of the device. It can potentially replace 3-4 existing technologies on the market and has the advantage that it imitates the normal physiological process. Hence, the name Fecobionics since it is an “electronics in biology” device that imitates defecation. The market potential is huge considering the high percentage of patients in the Western population with anorectal disorders including constipation and fecal incontinence.